Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.45 |
| ▸ | HTR2A | P28223 | 14/20 | 0.45 |
| ▸ | HTR2B | P41595 | 11/20 | 0.45 |
| ▸ | PNMT | P11086 | 3/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL6499039 | 0.89 | HTR2C (0.37) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| Fumaric Acid SCHEMBL6499043 | 0.89 | HTR2C (0.37) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL5739665 | 0.85 | HTR2C (0.57) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL5739712 | 0.85 | HTR2C (0.54) | HTR2CHTR2AHTR2BPNMTADRA2A | |
| SCHEMBL6488159 | 0.82 | HTR2C (0.61) | HTR2CHTR2AHTR2B | |
| SCHEMBL6499399 | 0.82 | HTR2C (0.46) | HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL6495632 | 0.79 | HTR2C (0.47) | HTR2CHTR2AHTR2BPNMTHTR6 | |
| SCHEMBL6494115 | 0.79 | HTR2C (0.40) | HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL6850359 | 0.79 | HTR2C (0.60) | HTR2CHTR2AHTR2BPNMTHTR6 | |
| SCHEMBL6481894 | 0.79 | HTR2C (0.42) | HTR2CHTR2AHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | PFIZER | 2005-12-22 | — | — | US | claimed |
| EP-1173440-B1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | PHARMACIA & UPJOHN COMPANY | 2002-12-26 | — | — | US | claimed |
| JP-2002543080-A | — | — | 2002-12-17 | — | — | JP | claimed |
| EP-1173440-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000064899-A1 | TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282796-A1 | Tetracyclic azepinoindole compounds | TBXA2R, NPY5R, AZI2 | HTR2C 22/4885HTR2A 34/4885HTR2B 86/4885 |
| US-20020198190-A1 | Tetracyclic azepinoindole compounds | TPH1, AZI2, CYP1A2 | HTR2C 24/4885HTR2A 43/4885HTR2B 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.